© Unternehmenskommunikation Charité
Translational research at the DKTK Partner site Berlin is dedicated to tackling the most demanding clinical challenges in cancer: Treatment failure and resistance, metastasis, tumor heterogeneity, cancer stemness and immune evasion.
By employing systems-based, integrative strategies molecular alterations and functionalities in solid and hematological malignancies are explored, aiming at the identification of mechanism-based biomarkers and application of biology-driven therapeutic concepts.
Charité´s key assets are large well characterized patient cohorts comprising diseases such as G.I. cancers, breast and ovarian cancer, melanoma, neuroblastoma, lymphoma, childhood and adult leukemia, neuroendocrine malignancies as well as head and neck cancer.
Important components of existing infrastructure platforms include metabolomics, proteomics, next generation sequencing, especially panel-based sequencing, vital tissue sections and preclinical imaging and flow cytometry / CyTOF2 facilities.
Owing to the site’s focus on functional genomics, advanced pre-clinical model systems (genetically modified mouse models, patient tumor-derived xenografts and 3-dimensional organoid cultures) permitting mechanism-based functional exploration and screening in prioritized tumor entities such as lymphoma, pediatric malignancies, including ALL, colorectal and head&neck cancer as well as transgenic technologies (advanced CRISPR/Cas9 knock-out approaches, human T cell receptor transgenics) were employed/reproached.
Prof Dr Manfred Dietel
Program "Molecular Diagnostics, Early Detection, and Biomarker Development (MDEB)"